Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$10.97B$10.97Bderived+7.2% vs Q4 2023 Net Income$9.23B$9.23Bderived+479.0% vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$1,911,000,000+7.4% Operating Cash Flowderived$2,868,000,000−5.6% Free Cash Flowderived$2,148,000,000−5.9% Margins · derivedOperating margin17.4%+0.0 pt vs Q4 2023
Net margin84.1%+68.5 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 21, 2025 · 52 d after period end